Medarex Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Medarex's estimated annual revenue is currently $18M per year.(i)
  • Medarex's estimated revenue per employee is $155,000

Employee Data

  • Medarex has 116 Employees.(i)
  • Medarex grew their employee count by -2% last year.

Medarex's People

NameTitleEmail/Phone
1
Associate Scientist 1 PPDReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.7M562%N/AN/A
#2
$0.2M10%N/AN/A
#3
$5.7M37-33%N/AN/A
#4
$114.8M5296%N/AN/A
#5
$0.8M50%N/AN/A
#6
$0.6M40%N/AN/A
#7
$14.7M83-22%$206.4MN/A
#8
$492.2M1834-15%$568MN/A
#9
$1.9M1271%N/AN/A
#10
$4.8M317%N/AN/A
Add Company

What Is Medarex?

Medarex is a biopharmaceutical company focused on the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs.

keywords:N/A

N/A

Total Funding

116

Number of Employees

$18M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Medarex News

2022-04-13 - Oxford BioTherapeutics Grants Third Exclusive License to ...

... as other world leaders in antibody development (such as Amgen, Immunogen, WuXi, Medarex (BMS), Alere (Abbott), BioWa, and Nerviano).

2022-04-06 - Bradycardia Market to Witness Growth Acceleration | Alchem ...

... Katsura Chemical, Lepu Medical, Livanova, Medarex, Medico, Medtronic, Merck, Minsheng Group, Nexus Pharmaceuticals, Nihon Kohden, Oscor,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25.5M116-2%N/A
#2
$16.8M1167%N/A
#3
$11.8M11633%N/A
#4
$13.9M11618%N/A
#5
$23.5M1174%N/A